KCT0000280进行中（未招募）未知
Dendritic cell-based Immunotherapy in patients with primary glioblastoma multiforme -Phase I/IIa clinical trial
Bundang CHA General Hospital0 个研究点目标入组 13 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 70(Year)（—）
- 性别
- All
入选标准
- •1. Among patients with glioblastoma(WHO Grade IV) by histological examination, a patient conformed state by resectable treatment including biopsy and having a plan to receive radiotherapy.
- •2. A patient aged over 20, until 70
- •3. KPS > 60
- •4. A patient over 3 months survival expected
- •5. A patinet wired up cancer antigen which is needed to make
- •investigational drug before starting clinical trial
- •6. Hemoglobin > 10.0 g/dL, WBC > 3,500/µL, PLT > 100,000/µL
- •Creatinine = 1.5 times of normal upper limit
- •SGOT/SGPT = 3 times of normal upper limit
- •7. A patient who signed the written consent form by oneself
排除标准
- •1. A patient with cardiopulmonary disability judged by the investigator
- •2. A patinet needed antibiotic treatment due to serious infection, HIV infection
- •3. A patinet with heart, liver, lung or kidney disability
- •4. A patient with the medical history of autoimmune disease or with immunodeficiency or autoimmune disease that might be aggravated by immunotherapy
- •5. A pregnant woman, breast-feeding woman or woman who wants to be pregnant during the trial period
- •6. A patient with uncontrolled hypertension or hypotension
- •7. A patient can't have dopamine or other pressor-agents
- •8. A patient with hypersensitivity reaction about phosphoprotein including interleukin-2
研究者
相似试验
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
进行中（未招募）
1 期
Dendritic cell-based immunotherapy for advanced solid tumours of children and young adultsChildren and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.EUCTR2013-003632-71-ESClínica Universidad de Navarra/Universidad de Navarra10
已完成
不适用
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSIhereditary non-polyposis colorectal cancerLynch syndrome100836241001799010027656NL-OMON39056niversitair Medisch Centrum Sint Radboud25
进行中（未招募）
1 期
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI - DC vaccination in lynch syndrome patientsIn this study our primary objective is to induce or enhance an immune response to tumor antigens in Lynch syndrome mutation carriers (with and without colorectal adenomas or carcinomas) and patients with sporadic colorectal cancer (CRC) showing microsatellite instability (MSI-high), the hallmark of MMR dysfunction, and test the hypothesis that DC vaccination might be effective as prophylactic treatment in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome mutation carriers.EUCTR2008-005584-33-NLRadboud University Nijmegen Medical Centre25